Home › Alexion's Soliris (eculizumab) Receives Orphan Drug Designation For The Treatment Of Neuromyelitis Optica (NMO)
 

Keywords :   


Alexion's Soliris (eculizumab) Receives Orphan Drug Designation For The Treatment Of Neuromyelitis Optica (NMO)

2013-06-27 18:50:00| drugdiscoveryonline News Articles

Alexion Pharmaceuticals, Inc. recently announced that Soliris (eculizumab), the company’s first-in-class terminal complement inhibitor, has been granted an orphan drug designation by the U.S. Food and Drug Administration (FDA) for the treatment of neuromyelitis optica (NMO), a life-threatening, ultra-rare neurological disorder

Tags: treatment drug receives designation

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
07.11Ralco acquires Sow Magic
07.11H5N1 pigs likely became infected from contact with migratory birds
07.11BioMADE Announces $26.9 Million Invested in 17 Projects
07.11Hurricane Rafael Graphics
07.11Hurricane Rafael Public Advisory Number 15A
07.11Summary for Hurricane Rafael (AT3/AL182024)
07.11Atlantic Tropical Weather Outlook
07.11Eastern North Pacific Tropical Weather Outlook
More »